Clinical Trials Browser

Phase 2 × Active not recruiting × pembrolizumab × Clear all

NCT04164082 2026-03-18

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT04548752 2026-03-18

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04708418 2026-03-18

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

Phase 2 Active not recruiting

Melanoma

NCT05172258 2026-03-18

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05217446 2026-03-18

SEAMARK

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03485209 2026-03-16

innovaTV 207

Phase 2 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT03360890 2026-03-13

iPRIME

Phase 2 Active not recruiting

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Phase 2 Active not recruiting

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT04736173 2026-03-09

ARC-10

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06604858 2026-03-09

TELESCOPE

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04214249 2026-03-04

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Phase 2 Active not recruiting

49 enrolled 32 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04895722 2026-03-04

MK-1308A-008

Phase 2 Active not recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06984328 2026-03-03

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Phase 2 Active not recruiting

Melanoma, Recurrence

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT04104893 2026-02-27

CHOMP

Phase 2 Active not recruiting

Turcot syndrome, Prostatic Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT03407144 2026-02-19

MK-3475-667

Phase 2 Active not recruiting

Hodgkin Disease

NCT04150900 2026-02-19

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Phase 2 Active not recruiting

7 enrolled 11 charts

Carcinoma, Squamous Cell

NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02816021 2026-02-17

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma

NCT06041802 2026-02-17

MK-3475A-E39

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT05805501 2026-02-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Phase 2 Active not recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT03519997 2026-02-11

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

35 enrolled 10 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05186974 2026-02-11

EVOKE-02

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05761951 2026-02-11

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT05775289 2026-02-11

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT03405792 2026-02-06

2-THE-TOP

Phase 2 Active not recruiting

40 enrolled 11 charts

Glioblastoma

NCT05980000 2026-02-06

Rambro2

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04895735 2026-02-02

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Phase 2 Active not recruiting

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT04340882 2026-01-30

DoceRamPem

Phase 2 Active not recruiting

Lung Neoplasms

NCT07376317 2026-01-29

OTIMAS

Phase 2 Active not recruiting

Melanoma

NCT02690558 2026-01-28

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Active not recruiting

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT02769520 2026-01-28

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT05366166 2026-01-28

Pembrolizumab Plus Olaparib in LA-HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05816252 2026-01-27

MK-2870-003

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02411656 2026-01-23

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Phase 2 Active not recruiting

71 enrolled 11 charts

Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03468218 2026-01-23

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Phase 2 Active not recruiting

36 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT05036434 2026-01-23

ACCOMPLISH

Phase 2 Active not recruiting

Adrenocortical Carcinoma

NCT02971748 2026-01-22

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Phase 2 Active not recruiting

36 enrolled 8 charts

Inflammatory Breast Neoplasms

NCT04166487 2026-01-21

Plasma-Adapted First-Line Pembro In NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03257163 2026-01-20

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Phase 2 Active not recruiting

110 enrolled 26 charts

Breast Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06232564 2026-01-14

PELICAN

Phase 2 Active not recruiting

Neuroendocrine Tumors